Senate marks Rare Disease Day to spotlight 30M Americans with forgotten illnesses
S.Res. 620 — A resolution designating February 28, 2026, as "Rare Disease Day". · Filed by John Barrasso (R-WY) · 5 cosponsors · Introduced Feb 26, 2026 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This resolution designates February 28, 2026, as 'Rare Disease Day' in the United States, recognizing the 30+ million Americans living with rare diseases and the challenges they face in obtaining diagnoses and treatments. The resolution acknowledges the Orphan Drug Act's 43-year legacy and calls for continued support of research, awareness, and regulatory innovation to develop treatments for the 95% of rare diseases still lacking FDA-approved therapies.
Why we flagged it
This is a straightforward Senate resolution designating a single day for public awareness and recognition of rare diseases. It contains no legislative mechanism, appropriations, or regulatory change—only a symbolic designation and a call to recognize the importance of rare disease research and treatment.
What the text implies
- The resolution's emphasis on the Orphan Drug Act and FDA approval rates may indirectly signal support for continued or expanded orphan drug incentives, though no specific legislative action is proposed here.
- By highlighting that 95% of rare diseases lack FDA-approved treatments, the resolution creates a rhetorical foundation for future legislative proposals to accelerate rare-disease drug development or expand incentives.
Who it affects
This is a symbolic designation that raises awareness of rare diseases affecting 30+ million Americans and their families, supporting continued research and regulatory focus on treatments for conditions that are otherwise neglected by the market. It carries no direct cost to citizens and affirms public commitment to addressing a genuine health equity gap.
Who stands to gain
- pharmaceutical companies developing orphan drugs
- biotech firms focused on rare disease treatments
Named in the bill
Senate, Barrasso, Blumenthal, Orphan Drug Act, FDA, Food and Drug Administration, National Institutes of Health, Center for Drug Evaluation and Research, Accelerating Rare disease Cures Program
Where it stands
5 cosponsors: 3 Democrats, 2 Republicans.
- Feb 26, 2026 — Passed the Senate · Congress.gov: “Passed/agreed to in Senate: Submitted in the Senate, considered, and agreed to without amendment and with a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 5, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Senate marks Rare Disease Day to spotlight 30M Americans with forgotten illnesses” QuorumCivic. https://share.quorumcivic.app/bill/119/sres620 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.